The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.

An immunofluorescence image of an aged mouse liver. Expression of β-galactosidase (white ... the primary challenge to ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...